TITLE:
A Pilot Study to Compare the Antiviral and Immunologic Effects of Stavudine ( d4T ) Versus Placebo in Subjects With Evidence of Recent HIV Infection.

CONDITION:
HIV Infections

INTERVENTION:
Stavudine

SUMMARY:

      To compare the antiviral effect of stavudine ( d4T ) versus placebo in patients with
      evidence of recent HIV infection.

      Also, to compare the immunologic effects and effects on quality of life of d4T in these
      patients.
    

DETAILED DESCRIPTION:

      Patients receive d4T or placebo every 12 hours for 4 weeks, after which dose decreases (or
      placebo) every 12 hours. Treatment continues for at least 48 weeks.
    

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria

        Patients must have:

          -  Recent HIV infection.

          -  No prior antiretroviral therapy.

          -  No acute opportunistic infection at study entry.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following symptoms or conditions are excluded:

          -  Intractable diarrhea.

          -  Bilateral peripheral neuropathy.

          -  Any other condition that would preclude study therapy.

        Concurrent Medication:

        Excluded:

          -  Myelosuppressive, neurotoxic, or hepatotoxic drugs.

        Patients with the following prior condition are excluded:

        History of bilateral peripheral neuropathy.

        Prior Medication:

        Excluded:

          -  Prior antiretroviral therapy.

          -  Myelosuppressive, neurotoxic, or cytotoxic agents within 3 months prior to study
             entry.
      
